Clinical Trials Browser

Phase 1/2 × Cholangiocarcinoma × tislelizumab × Clear all

NCT04782804 2022-08-18

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Phase 1/2 Unknown

Gastrointestinal

Cholangiocarcinoma